S. White

Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes

S. Neubauer, L. Hodson, J. Cobbold, 2019, JGH open : an open access journal of gastroenterology and hepatology.

Randomized controlled trial comparing impact on platelet reactivity of twice‐daily with once‐daily aspirin in people with Type 2 diabetes

R. Holman, A. Oulhaj, H. Sourij, 2016, Diabetic medicine : a journal of the British Diabetic Association.

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients

J. Holst, R. Holman, K. Owen, 2020, Endocrinology, diabetes & metabolism.

Evaluation of a Self-Administered Oral Glucose Tolerance Test

R. Holman, H. Sourij, H. Price, 2013, Diabetes Care.

Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids.

A. Isidori, L. Hodson, N. Nikolaou, 2020, The Journal of clinical endocrinology and metabolism.

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

R. Holman, R. Eastell, R. Sadler, 2023, Nature Communications.